Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1979 1
1983 5
1986 2
1987 38
1988 104
1989 121
1990 146
1991 138
1992 174
1993 203
1994 202
1995 221
1996 296
1997 335
1998 415
1999 431
2000 434
2001 460
2002 471
2003 509
2004 431
2005 427
2006 451
2007 460
2008 509
2009 482
2010 497
2011 527
2012 551
2013 633
2014 1073
2015 1550
2016 1183
2017 991
2018 1418
2019 1507
2020 1708
2021 1939
2022 1762
2023 1466
2024 709
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,116 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for klinikum t
Search for Kliniken T instead (1 results)
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedo C, Soengas MS, Bald T, Huber S, Endres S, Kobold S. Briukhovetska D, et al. Immunity. 2023 Jan 10;56(1):143-161.e11. doi: 10.1016/j.immuni.2022.12.010. Immunity. 2023. PMID: 36630913 Free PMC article.
Although T cells can exert potent anti-tumor immunity, a subset of T helper (Th) cells producing interleukin-22 (IL-22) in breast and lung tumors is linked to dismal patient outcome. Here, we examined the mechanisms whereby these T cells contribute to disease …
Although T cells can exert potent anti-tumor immunity, a subset of T helper (Th) cells producing interleukin-22 (IL-22) in bre …
Utilizing chemokines in cancer immunotherapy.
Märkl F, Huynh D, Endres S, Kobold S. Märkl F, et al. Trends Cancer. 2022 Aug;8(8):670-682. doi: 10.1016/j.trecan.2022.04.001. Epub 2022 Apr 29. Trends Cancer. 2022. PMID: 35501268 Review.
Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many cancer types. However, most patients do not respond to immunotherapies or relapse after an initial response, stressing the need for improved …
Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many …
Spatial proteomics in three-dimensional intact specimens.
Bhatia HS, Brunner AD, Öztürk F, Kapoor S, Rong Z, Mai H, Thielert M, Ali M, Al-Maskari R, Paetzold JC, Kofler F, Todorov MI, Molbay M, Kolabas ZI, Negwer M, Hoeher L, Steinke H, Dima A, Gupta B, Kaltenecker D, Caliskan ÖS, Brandt D, Krahmer N, Müller S, Lichtenthaler SF, Hellal F, Bechmann I, Menze B, Theis F, Mann M, Ertürk A. Bhatia HS, et al. Cell. 2022 Dec 22;185(26):5040-5058.e19. doi: 10.1016/j.cell.2022.11.021. Cell. 2022. PMID: 36563667 Free article.
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
Glaser V, Flugel C, Kath J, Du W, Drosdek V, Franke C, Stein M, Pruß A, Schmueck-Henneresse M, Volk HD, Reinke P, Wagner DL. Glaser V, et al. Genome Biol. 2023 Apr 24;24(1):89. doi: 10.1186/s13059-023-02928-7. Genome Biol. 2023. PMID: 37095570 Free PMC article.
We demonstrate efficient insertion of a CAR into the T cell receptor alpha constant (TRAC) gene, along with two knock-outs that silence major histocompatibility complexes (MHC) class I and II expression. ...Combining Cas12a Ultra for CAR knock-in and a Cas9-derived base ed …
We demonstrate efficient insertion of a CAR into the T cell receptor alpha constant (TRAC) gene, along with two knock-outs that silen …
Neutrophil "plucking" on megakaryocytes drives platelet production and boosts cardiovascular disease.
Petzold T, Zhang Z, Ballesteros I, Saleh I, Polzin A, Thienel M, Liu L, Ul Ain Q, Ehreiser V, Weber C, Kilani B, Mertsch P, Götschke J, Cremer S, Fu W, Lorenz M, Ishikawa-Ankerhold H, Raatz E, El-Nemr S, Görlach A, Marhuenda E, Stark K, Pircher J, Stegner D, Gieger C, Schmidt-Supprian M, Gaertner F, Almendros I, Kelm M, Schulz C, Hidalgo A, Massberg S. Petzold T, et al. Immunity. 2022 Dec 13;55(12):2285-2299.e7. doi: 10.1016/j.immuni.2022.10.001. Epub 2022 Oct 21. Immunity. 2022. PMID: 36272416 Free PMC article.
[Reconstructive urology].
Kälble T, Fisch M, Manseck A. Kälble T, et al. Urologe A. 2020 Apr;59(4):397. doi: 10.1007/s00120-020-01162-4. Urologe A. 2020. PMID: 32296887 German. No abstract available.
High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction.
Ellingsen Ø, Halle M, Conraads V, Støylen A, Dalen H, Delagardelle C, Larsen AI, Hole T, Mezzani A, Van Craenenbroeck EM, Videm V, Beckers P, Christle JW, Winzer E, Mangner N, Woitek F, Höllriegel R, Pressler A, Monk-Hansen T, Snoer M, Feiereisen P, Valborgland T, Kjekshus J, Hambrecht R, Gielen S, Karlsen T, Prescott E, Linke A; SMARTEX Heart Failure Study (Study of Myocardial Recovery After Exercise Training in Heart Failure) Group. Ellingsen Ø, et al. Circulation. 2017 Feb 28;135(9):839-849. doi: 10.1161/CIRCULATIONAHA.116.022924. Epub 2017 Jan 12. Circulation. 2017. PMID: 28082387 Free PMC article. Clinical Trial.
[Incontinence].
Kälble T, Lümmen G. Kälble T, et al. Urologe A. 2017 Dec;56(12):1531. doi: 10.1007/s00120-017-0532-z. Urologe A. 2017. PMID: 29147732 German. No abstract available.
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S. Liebers N, et al. Blood Adv. 2021 Jul 13;5(13):2707-2716. doi: 10.1182/bloodadvances.2020004155. Blood Adv. 2021. PMID: 34196677 Free PMC article.
In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-r …
In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination …
22,116 results
You have reached the last available page of results. Please see the User Guide for more information.